Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT

This article was originally published in The Pink Sheet Daily

Executive Summary

QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.

You may also be interested in...



QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone

Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.

QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone

Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.

QLT Aczone Clears FDA With Restricted Indication

Labeling calls for testing for glucose 6-phosphate dehydrogenase deficiency before initiating treatment with Aczone (dapsone); patients with the enzyme deficiency should be monitored with regular blood counts. Patients are also advised to consider other acne therapies.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel